Guiding principles for mechanistic modeling of bispecific antibodies

Baeuerle, 2009, Bispecific T-cell engaging antibodies for cancer therapy. Cancer research, AACR, 69, 4941 Brodfuehrer, 2014, Quantitative analysis of target coverage and germinal center response by a CXCL13 neutralizing antibody in a T-dependent mouse immunization model, 31, 635 Chames, 2009, 539 Chudasama, 2015, Simulations of site-specific target-mediated pharmacokinetic models for guiding the development of bispecific antibodies, 42, 1 Davies, 1993, Physiological parameters in laboratory animals and humans, 10, 1093 Dirks, 2010, Population pharmacokinetics of therapeutic monoclonal antibodies, 49, 633 Fan, 2015, Bispecific antibodies and their applications, J. Hematol. Oncol. BioMed Central, 8, 130, 10.1186/s13045-015-0227-0 Foote, 1995, Kinetic and affinity limits on antibodies produced during immune responses, 92, 1254 Gibiansky, 2011 Gibiansky, 2009, Target-mediated drug disposition model: relationships with indirect response models and application to population PK–PD analysis, 36, 341 Jin, 2015, J. Pharmacokinet. Pharmacodyn., 42, 11 Kontermann, 2015, vol. 20, 838 Le Dirks, 2010 Rhoden, 2016, A modeling and experimental investigation of the effects of antigen density, binding affinity, and antigen expression ratio on bispecific antibody binding to cell surface targets, J. Biol. Chem., 291, 11337, 10.1074/jbc.M116.714287 Singh, 2015, Quantitative prediction of human pharmacokinetics for mAbs exhibiting target-mediated disposition, 17, 389 Tiwari, 2016, Assessing the impact of tissue target concentration data on uncertainty in in vivo target coverage predictions. CPT: pharmacometrics & systems pharmacology, Wiley Online Library, 5, 565 Tiwari, 2017, Optimal affinity of a monoclonal antibody: guiding principles using mechanistic modeling, 19, 510 Yang, 2016, vol. 18, 48